Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antibody, checkpoint, immune, inhibitor, outcome, test, trial | 4 Comments »
We are well aware that many patients are interested in the potential of “natural products” as effective and safe forms of treatment for cancer. … READ MORE …
Filed under: Drugs in development | Tagged: activity, anethole, natural, product | 2 Comments »
In January and May this year we had noted that a company called Churchill Pharmaceuticals has been developing a different formulation of ultramicron-sized, oral abiraterone acetate (to be called Yonsa™). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Churchill, formulation, submicron, Yonsa | 2 Comments »
At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial | Leave a comment »
